ATAI
randomized phase dose study in healthy volunteers followed by phase a open label study in | ATAI
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
19 of 34
Related slides by other companies
Erasca
Investor Presentation
August 2023
proposed pivotal phase trial designs creative strategy includes high randomized melanoma trial and tissue agnostic indication | Erasca
23andMe
Investor Presentation
February 2022
phase study of me in patients with locally advanced or metastatic solid malignancies design objectives | 23andMe
23andMe
Investor Presentation
August 2022
phase study of me in patients with locally advanced or metastatic solid malignancies study design objectives | 23andMe
Equillium
Investor Presentation
November 2023
phase study of in adults with moderate to severe target product profile alternative to with at least comparable efficacy patient administered weekly weekly subcutaneous injection similar to | Equillium
Other recent decks by ATAI
See all presentations (13 decks)
Investor Presentation
October 2023
Investor Conference
May 2023
Investor Presentation
April 2023
Investor Presentation
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights